Commercial Medical Devices

MHRA Opens Community of Practice for Digital Mental Health Technologies

The UK regulator's new forum pairs cross-sector shared learning with a survey meant to set its early priorities.

Ivo PetrovOctober 22, 20265 min read5 views
A translucent ring of connected glass-like nodes hovers above a pale surface, joined by thin glowing lines to abstract device and document forms in a soft teal and indigo studio setting.

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, a forum the agency describes as a step towards stronger regulatory understanding, shared learning and practical support for developers working in one of the fastest-growing areas of UK medtech.

Announced on the MHRA's official blog, the initiative is framed as a coordinated effort to help innovators navigate regulatory expectations, improve compliance and bring safe, effective digital mental health solutions into clinical use. According to the announcement, it answers growing demand for clarity on evidence requirements, post-market responsibilities and the changing regulatory landscape for software-based and AI-enabled mental health tools.

A forum spanning the sector

The community is intended to bring developers together with clinicians, researchers, commissioners and regulatory specialists so that best practice is understood in common. The announcement notes that as digital mental health technologies extend from therapeutic apps to AI-supported assessment tools, the need for consistent, practical guidance has become more urgent.

Stated objectives

The announcement lists the following aims for the community:

  • Supporting developers in interpreting regulatory requirements and embedding compliance earlier in product design.
  • Identifying common challenges faced by innovators, particularly small and medium-sized enterprises entering the mental health space.
  • Sharing real-world experience from organisations already working through regulatory pathways.
  • Strengthening dialogue between industry and regulators so that emerging technologies meet expectations on safety, performance and evidence.

The announcement presents the community as a route for the wider medtech development community to engage directly with the regulator on questions that often decide whether a promising technology reaches patients.

Survey to shape initial priorities

To set the community's first priorities, the MHRA has opened a survey for developers of digital mental health technologies and other stakeholders across the medtech ecosystem. It asks about current regulatory challenges, the areas where clearer guidance is needed and ways to improve compliance support.

The agency is seeking broad participation so that the community reflects real-world needs rather than top-down assumptions. For developers, the announcement positions the survey as a direct channel for influencing future regulatory support and for shaping a more predictable, transparent environment for innovation.

The survey can be reached through the MHRA announcement, and developers are encouraged to complete it and circulate it within their organisations. A strong response, the announcement states, will help the new community deliver practical support that accelerates safe, effective innovation for patients.